Page 168 - Genomic Medicine in Emerging Economies

References 157

Rebecchi, A., Gola, M., Kulkarni, M., Lettieri, E., Paoletti, I., Capolongo, S., 2016. Healthcare for
all in emerging countries: a preliminary investigation of facilities in Kolkata, India. Ann. Ist
Super Sanita 52, 88–97.
Saokaew, S., Tassaneeyakul, W., Maenthaisong, R., Chaiyakunapruk, N., 2014. Cost-effectiveness
analysis of HLA-B* 5801 testing in preventing allopurinol-induced SJS/TEN in Thai popula-
tion. PLoS One 9, e94294.
Schwander, B., Gradl, B., Zöllner, Y., Lindgren, P., Diener, H.-C., Lüders, S., et al., 2009. Cost-utility
analysis of eprosartan compared to enalapril in primary prevention and nitrendipine in sec-
ondary prevention in Europe–the HEALTH model. Value Health 12, 857–871.
Shah, S.V., Gage, B.F., 2011. Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibril-
lation. Circulation, 110.985655.
Sharma, M., Seoud, M., Kim, J.J., 2017. Cost-effectiveness of increasing cervical cancer screening
coverage in the Middle East: an example from Lebanon. Vaccine 35, 564–569.
Somkrua, R., Eickman, E.E., Saokaew, S., Lohitnavy, M., Chaiyakunapruk, N., 2011. Association of
HLA-B* 5801 allele and allopurinol-induced Stevens Johnson syndrome and toxic epidermal
necrolysis: a systematic review and meta-analysis. BMC Med. Genet. 12, 118.
Tangamornsuksan, W., Chaiyakunapruk, N., Somkrua, R., Lohitnavy, M., Tassaneeyakul, W., 2013.
Relationship between the HLA-B* 1502 allele and carbamazepine-induced Stevens-Johnson
syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis. JAMA Der-
matol. 149, 1025–1032.
Verhoef, T.I., Redekop, W.K., De Boer, A., Maitland-Van Der Zee, A.H., group, E.-P., 2015. Economic
evaluation of a pharmacogenetic dosing algorithm for coumarin anticoagulants in the Nether-
lands. Pharmacogenomics 16, 101–114.
Verhoef, T.I., Redekop, W.K., Van Schie, R.M., Bayat, S., Daly, A.K., Geitona, M., et al., 2012. Cost-
effectiveness of pharmacogenetics in anticoagulation: international differences in healthcare
systems and costs. Pharmacogenomics 13, 1405–1417.
Verhoef, T.I., Redekop, W.K., Veenstra, D.L., Thariani, R., Beltman, P.A., Van Schie, R.M., et al.,
2013. Cost-effectiveness of pharmacogenetic-guided dosing of phenprocoumon in atrial fibril-
lation. Pharmacogenomics 14, 869–883.
Vijayaraghavan, A., Efrusy, M., Lindeque, G., Dreyer, G., Santas, C., 2009. Cost effectiveness of
high-risk HPV DNA testing for cervical cancer screening in South Africa. Gynecol. Oncol. 112,
377–383.
Wallentin, L., Yusuf, S., Ezekowitz, M.D., Alings, M., Flather, M., Franzosi, M.G., et al., 2010. Ef-
ficacy and safety of dabigatran compared with warfarin at different levels of international nor-
malised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial.
Lancet 376, 975–983.
Zhang, M., Wang, W., Millar, R., Li, G., Yan, F., 2017. Coping and compromise: a qualitative study
of how primary health care providers respond to health reform in China. Hum. Resour. Health
15, 50.